Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
08 mars 2022 02h00 HE
|
INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
08 mars 2022 02h00 HE
|
INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Global Artificial Intelligence (AI) in Drug Discovery Market ($4197.5 Mn by 2028) Growth Forecast at 41.5% CAGR During 2022 to 2028 COVID Impact and Global Analysis by Vantage Market Research
03 mars 2022 04h49 HE
|
Vantage Market Research
WASHINGTON, March 03, 2022 (GLOBE NEWSWIRE) -- The Global Artificial Intelligence in Drug Discovery Market size is expected to reach USD 4,197.5 Million by 2028, exhibiting a Compound Annual Growth...
BioRestorative Therapies Announces Closing of $23 Million Public Offering
09 nov. 2021 14h20 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced...
Wereldhave commits to setting Science-Based Targets
13 mars 2020 03h29 HE
|
Wereldhave N.V.
Press release | Wereldhave commits to setting Science-Based TargetsWereldhave is pleased to announce it has committed itself to reduce carbon emissions to a level in line with what climate science...
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
21 janv. 2020 09h15 HE
|
Ritter Pharmaceuticals, Inc.
Transaction to Create a Nasdaq-listed Biotechnology Company Focused on Advancing Qualigen’s Cancer and Infectious Disease Therapeutic Development Programs LOS ANGELES, Jan. 21, 2020 (GLOBE...
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program
12 déc. 2019 09h45 HE
|
BioRestorative Therapies, Inc.
MELVILLE, N.Y., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today...
BioRestorative Therapies Receives A Second Patent in Australia For Its Metabolic Program
23 oct. 2019 09h45 HE
|
BioRestorative Therapies, Inc.
MELVILLE, N.Y., Oct. 23, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the...
Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives
07 oct. 2019 09h00 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that...
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
04 déc. 2018 08h30 HE
|
Ritter Pharmaceuticals, Inc.
Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...